Table 4.
Baseline characteristics of 403 treatment-naïve patients with chronic hepatitis B
| Characteristics | Pre-existing rtM204I n = 17 | Wild type rtM204 n = 386 | P value |
| Gender (M/F) | 14/3 | 230/156 | 0.060 |
| Age (yr) | 48.8 ± 9.3 | 43.7 ± 12.6 | 0.101 |
| HBeAg (positive/negative) | 10/7 | 228/158 | 0.984 |
| HBV-DNA (log10 IU/mL) | 6.33 ± 0.66 | 6.06 ± 1.77 | 0.519 |
| qHBsAg (log 10 IU/mL) | 3.43 ± 0.30 | 3.59 ± 0.70 | 0.334 |
| AST (IU/L) | 104.7 ± 40.9 | 78.7 ± 65.2 | 0.103 |
| ALT (IU/L) | 77.8 ± 29.4 | 85.4 ± 84.1 | 0.709 |
| Total bilirubin (mg/dL) | 0.93 ± 0.33 | 0.88 ± 0.60 | 0.743 |
| Albumin (g/dL) | 4.02 ± 0.43 | 4.14 ± 0.52 | 0.338 |
| Prothrombin time (INR) | 1.07 ± 0.10 | 1.02 ± 0.16 | 0.246 |
| Platelet count (× 103/mm3) | 155.7 ± 55.6 | 181.4 ± 64.4 | 0.106 |
| FIB-4 | 4.38 ± 2.33 | 2.91 ± 2.92 | 0.041 |
| APRI | 1.94 ± 0.98 | 1.34 ± 1.35 | 0.068 |
| Significant fibrosis1 (presence/absence) | 12/5 | 145/241 | 0.006 |
| Liver cirrhosis (presence/absence) | 7/10 | 80 / 306 | 0.045 |
| HCC (presence/absence) | 5/12 | 46 / 340 | 0.034 |
1
Significant fibrosis was defined as aspartate aminotransferase to platelet ratio index > 1.5 or fibrosis-4 index > 3.25. ALT: Alanine aminotransferase; APRI: Aspartate aminotransferase to platelet ratio index; AST: Aspartate aminotransferase; FIB-4: Fibrosis-4 Index; HCC: Hepatocellular carcinoma; INR: International normalized ratio; qHBsAg: Quantitative hepatitis B surface antigen levels; HBV: Hepatitis B virus.